[go: up one dir, main page]

AR059225A1 - Sal de citrato, proceso de preparacion y su actividad en terapia - Google Patents

Sal de citrato, proceso de preparacion y su actividad en terapia

Info

Publication number
AR059225A1
AR059225A1 ARP070100366A ARP070100366A AR059225A1 AR 059225 A1 AR059225 A1 AR 059225A1 AR P070100366 A ARP070100366 A AR P070100366A AR P070100366 A ARP070100366 A AR P070100366A AR 059225 A1 AR059225 A1 AR 059225A1
Authority
AR
Argentina
Prior art keywords
therapy
activity
preparation process
citrate salt
salt
Prior art date
Application number
ARP070100366A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR059225A1 publication Critical patent/AR059225A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se relaciona con una nueva sal farmacéuticamente aceptable, el citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1H-indol-5-carbonitrilo, con un proceso para su preparacion, con formulaciones farmacéuticas que contienen dicha sal y con el uso de dicha sal activa en terapia y, en especial en afecciones y trastornos relacionados con la GSK3.
ARP070100366A 2006-02-02 2007-01-29 Sal de citrato, proceso de preparacion y su actividad en terapia AR059225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76455106P 2006-02-02 2006-02-02

Publications (1)

Publication Number Publication Date
AR059225A1 true AR059225A1 (es) 2008-03-19

Family

ID=38327680

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100366A AR059225A1 (es) 2006-02-02 2007-01-29 Sal de citrato, proceso de preparacion y su actividad en terapia

Country Status (24)

Country Link
US (2) US8008294B2 (es)
EP (1) EP1981869A4 (es)
JP (1) JP2009525324A (es)
KR (1) KR20080098022A (es)
CN (2) CN101379053A (es)
AR (1) AR059225A1 (es)
AU (1) AU2007210336B2 (es)
BR (1) BRPI0706745A2 (es)
CA (1) CA2641900A1 (es)
EC (1) ECSP088647A (es)
IL (1) IL192888A0 (es)
MX (1) MX2008009719A (es)
MY (1) MY146102A (es)
NO (1) NO20083784L (es)
NZ (1) NZ570849A (es)
PE (1) PE20090192A1 (es)
RU (1) RU2415137C2 (es)
SA (1) SA07280004B1 (es)
SG (1) SG169381A1 (es)
TW (1) TW200800977A (es)
UA (1) UA94251C2 (es)
UY (1) UY30126A1 (es)
WO (1) WO2007089191A1 (es)
ZA (1) ZA200806725B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
KR20090129479A (ko) * 2007-04-18 2009-12-16 아스트라제네카 아베 화합물 2-히드록시-3-[5-(모르폴린-4-일메틸)피리딘-2-일]1ｈ-인돌-5-카르보니트릴 701의 신규 제조 방법
US20100267720A1 (en) * 2007-07-30 2010-10-21 Astrazeneca Ab Crystalline Forms of 2-Hydroxy-3- [5- (Morpholin- 4- Ylmethyl) Pyridin-2-YL] IH- Indole- 5 -Carbonitrile Citrate
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
TW202204348A (zh) * 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008089A (es) 2001-04-05 2004-01-22 Torrent Pharmaceuticals Ltd Compuestos heterociclicos para complicaciones relacionadas con el envejecimiento y vasculares diabeticas.
JP2003009588A (ja) 2001-06-20 2003-01-10 Toshiba Corp 車両連続運転装置用インバータ装置
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US20050054663A1 (en) * 2003-08-13 2005-03-10 Bennett Christina N. GSK-3 inhibitors
EP1833819A1 (en) 2004-12-30 2007-09-19 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات

Also Published As

Publication number Publication date
US20070203137A1 (en) 2007-08-30
EP1981869A4 (en) 2010-08-25
JP2009525324A (ja) 2009-07-09
CN101379053A (zh) 2009-03-04
UY30126A1 (es) 2007-09-28
MY146102A (en) 2012-06-29
AU2007210336A1 (en) 2007-08-09
ZA200806725B (en) 2009-07-29
UA94251C2 (ru) 2011-04-26
CN101378754A (zh) 2009-03-04
WO2007089191A1 (en) 2007-08-09
ECSP088647A (es) 2008-08-29
EP1981869A1 (en) 2008-10-22
AU2007210336B2 (en) 2011-03-24
RU2415137C2 (ru) 2011-03-27
US8008294B2 (en) 2011-08-30
NZ570849A (en) 2011-01-28
MX2008009719A (es) 2008-09-04
BRPI0706745A2 (pt) 2011-04-05
TW200800977A (en) 2008-01-01
NO20083784L (no) 2008-10-13
SA07280004B1 (ar) 2011-10-29
IL192888A0 (en) 2009-02-11
KR20080098022A (ko) 2008-11-06
RU2008131906A (ru) 2010-03-10
CA2641900A1 (en) 2007-08-09
US20090023732A1 (en) 2009-01-22
PE20090192A1 (es) 2009-03-20
SG169381A1 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
MX2009000507A (es) Espuma farmaceutica de acidos grasos.
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
AR059225A1 (es) Sal de citrato, proceso de preparacion y su actividad en terapia
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
NO20085414L (no) Farmasoytiske preparater for vedvarende frigivelse av fenylefrin
Iorizzo et al. Today's treatments options for onychomycosis
AR054238A1 (es) Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
WO2008051527A3 (en) Sustained release of agents for localized pain management
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
WO2007100282A8 (en) New salts of an indole derivative and their use in medicine
AR077909A1 (es) Intervenciones de urgencia de carbon vegetal activo con sobredosificacion con etexilato de dabigatran
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej

Legal Events

Date Code Title Description
FA Abandonment or withdrawal